CN109528545A - A kind of removing wrinkle and resisting aging active peptides - Google Patents
A kind of removing wrinkle and resisting aging active peptides Download PDFInfo
- Publication number
- CN109528545A CN109528545A CN201910057506.9A CN201910057506A CN109528545A CN 109528545 A CN109528545 A CN 109528545A CN 201910057506 A CN201910057506 A CN 201910057506A CN 109528545 A CN109528545 A CN 109528545A
- Authority
- CN
- China
- Prior art keywords
- resisting aging
- active peptides
- removing wrinkle
- wrinkle
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 103
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 101
- 230000037303 wrinkles Effects 0.000 title claims abstract description 82
- 230000032683 aging Effects 0.000 title claims abstract description 69
- 229920001184 polypeptide Polymers 0.000 claims abstract description 28
- 150000002632 lipids Chemical class 0.000 claims abstract description 6
- 239000006174 pH buffer Substances 0.000 claims abstract description 6
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 6
- 239000004094 surface-active agent Substances 0.000 claims abstract description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 57
- 238000002360 preparation method Methods 0.000 claims description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical group [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 18
- -1 Palmityl tetrapeptide -7 Chemical compound 0.000 claims description 12
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 11
- 229940083466 soybean lecithin Drugs 0.000 claims description 11
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 10
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 10
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 10
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 10
- 239000005642 Oleic acid Substances 0.000 claims description 10
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 10
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 10
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 claims description 7
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 claims description 7
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims description 7
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 7
- 108010087806 Carnosine Proteins 0.000 claims description 6
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 229940093441 palmitoyl oligopeptide Drugs 0.000 claims description 6
- OGNHOGPWQTWKGQ-VGWMRTNUSA-N (2S)-5-amino-2-[[(2S)-1-[2-[[(2S)-5-amino-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 OGNHOGPWQTWKGQ-VGWMRTNUSA-N 0.000 claims description 5
- GFEYWOGCSROPRT-OBXVVNIGSA-N (2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 GFEYWOGCSROPRT-OBXVVNIGSA-N 0.000 claims description 5
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical group CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 claims description 5
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 5
- 108010047657 Phe-Val-Ala-Pro-Phe-Pro Proteins 0.000 claims description 5
- 229940044199 carnosine Drugs 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- FYYQZWIXRQJNAC-RMAOKOMNSA-N NCCC(N(C[C@@H](C1)O)[C@@H]1C(C(C1=CC=CC=C1)NC(CCC(N)N)=O)=O)=O Chemical compound NCCC(N(C[C@@H](C1)O)[C@@H]1C(C(C1=CC=CC=C1)NC(CCC(N)N)=O)=O)=O FYYQZWIXRQJNAC-RMAOKOMNSA-N 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 3
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 3
- 235000013372 meat Nutrition 0.000 claims description 3
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims description 2
- AXPZIVKEZRHGAS-UHFFFAOYSA-N 3-benzyl-5-[(2-nitrophenoxy)methyl]oxolan-2-one Chemical compound [O-][N+](=O)C1=CC=CC=C1OCC1OC(=O)C(CC=2C=CC=CC=2)C1 AXPZIVKEZRHGAS-UHFFFAOYSA-N 0.000 claims description 2
- 239000005639 Lauric acid Substances 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 238000009825 accumulation Methods 0.000 abstract description 13
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 230000003679 aging effect Effects 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 2
- 206010040954 Skin wrinkling Diseases 0.000 description 58
- 210000003491 skin Anatomy 0.000 description 52
- 238000003756 stirring Methods 0.000 description 38
- 238000012360 testing method Methods 0.000 description 27
- 230000003712 anti-aging effect Effects 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 230000001153 anti-wrinkle effect Effects 0.000 description 18
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 18
- 235000019799 monosodium phosphate Nutrition 0.000 description 18
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 18
- 238000004945 emulsification Methods 0.000 description 17
- 238000012545 processing Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 229940051250 hexylene glycol Drugs 0.000 description 9
- SVTBMSDMJJWYQN-UHFFFAOYSA-N hexylene glycol Natural products CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 9
- 235000013772 propylene glycol Nutrition 0.000 description 9
- 230000037394 skin elasticity Effects 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 238000013112 stability test Methods 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000009759 skin aging Effects 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102000016942 Elastin Human genes 0.000 description 4
- 108010014258 Elastin Proteins 0.000 description 4
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 4
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 4
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 4
- 229920002549 elastin Polymers 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 1
- QGGBBQJHVCVVKM-XOBYPWAZSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amin Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(N)=O QGGBBQJHVCVVKM-XOBYPWAZSA-N 0.000 description 1
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 1
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 241000040710 Chela Species 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 description 1
- 229940078033 acetyl octapeptide-3 Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 description 1
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 1
- 108010091287 palmitoyl-glycyl-histidyl-lysine Proteins 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
The present invention discloses a kind of removing wrinkle and resisting aging active peptides, the polypeptide is wrapped in nano-encapsulated body with lipid components, nano-encapsulated body further includes polyalcohol, surfactant, pH buffer ingredient, the mass percentage concentration of removing wrinkle and resisting aging active peptides is 0.0001%-5%, the mass percentage concentration of lipid components is 2%-20%, the mass percentage concentration of polyalcohol is 2%-20%, and the mass percentage concentration of surfactant is 0.1%-10%, and the mass percentage concentration of pH buffer is 0.001%-1%.The stability of removing wrinkle and resisting aging active peptides of the present invention is good, highly-safe；It is easy to Transdermal absorption；Compared with before nano-encapsulated, removing wrinkle and resisting aging active peptides are higher in the accumulation of skin after nano-encapsulated, and same inventory can achieve superior removing wrinkle and resisting aging effect.
Description
Technical field
The invention belongs to skin care external drug fields, are related to a kind of removing wrinkle and resisting aging active peptides.
Background technique
The factor for influencing skin aging mainly has two major classes: endogenous factor and extrinsic factor.Inherent cause is to influence
The most important endogenous factor of skin aging shows as cutis laxa with advancing age, wrinkle generates.Extrinsic factor packet
Light aging, environmental pollution, bad habit etc. are included, wherein light aging is the main extrinsic factor for influencing skin aging, is shown as
Skin is dark yellow, pigmentation, relaxation, lacks flexibility, is coarse, is dry etc..
Active constituent in cosmetics for anti-aging is concentrated mainly in some plant extracts before polypeptide, is also had
With compounds such as vitamin Cs, since micromolecule polypeptide activity is high, more and more active peptides are used for skin nursing products and work as
In.Removing wrinkle and resisting aging active peptides can by adjusting neurotransmitter release and achieve the effect that adjust contraction of muscle, to dispel
Wrinkle, or the synthesis by promoting collagen, elastin laminin improve skin elasticity and compact degree, improve static wrinkle,
To anti-aging.However, often polypeptide moiety is added directly in prescription in existing removing wrinkle and resisting aging product, thus bring
The problem of be that stability is poor in the product for polypeptide so that originally there is high-efficiency activated removing wrinkle and resisting aging polypeptide to be unable to give full play
Its due effect, and the catabolite that polypeptide is degraded in the product and generated is possible to potentially hazardous to human body generation.
Further, since the presence of skin barrier, limits the exchange of inside and outside substance, the active peptides in product be can not be successfully through skin
Skin barrier is absorbed, and is also just difficult to give full play to its removing wrinkle and resisting aging effect.In order to increase Transdermal absorption, get a desired effect,
It needs to increase inventory, thus can bring the rising of cost.
Therefore, this field be badly in need of a kind of stability it is good, it is highly-safe, be easy to that Transdermal absorption, inventory be small, excellent effect,
It can make up for it the external preparation for skin skin-protection product or curable product of prior art defect.
Summary of the invention
Technical problem to be solved by the present invention lies in provide a kind of stability it is good, it is highly-safe, be easy to Transdermal absorption, throw
Doses is small, excellent effect removing wrinkle and resisting aging active peptides.
For this purpose, the removing wrinkle and resisting aging active peptides are to be wrapped in receive the present invention provides a kind of removing wrinkle and resisting aging active peptides
In rice inclusion enclave.
Removing wrinkle and resisting aging active peptides of the present invention are tripeptides -1, Argireline, acetyl group octapeptide -3, β-alanyl
Hydroxyprolyl- diaminobutyryl benzyl amide, Matrixyl -4, palmityl tetrapeptide -7, carnosine, -1 copper of tripeptides, palmityl three
Peptide -1, palmityl tripeptides -5, palmitoyl oligopeptide, hexapeptide -9, hexapeptide -11, each composition quality percentage concentration are 0.0001%-5%.
Package of the present invention is wrapped up with lipid components.
The lipid components are that soybean lecithin, egg yolk lecithin, phosphatidyl-ethanolamine, lysophosphatidyl choline, gallbladder are solid
Alcohol, lauric acid, myristic acid, palmitinic acid, stearic acid, isopropyl myristate, isopropyl palmitate, oleic acid, linoleic acid
The combination of one or more of ester, vitamin E, each composition quality percentage concentration are 2%-20%.
Nano-encapsulated body of the present invention further includes following component: polyalcohol, surfactant, pH buffer.
The polyalcohol is propylene glycol, glycerol, 1,2- hexylene glycol, the combination of one or more of 1,3-BDO, respectively
Composition quality percentage concentration is 2%-20%.
The surfactant is polysorbas20, polysorbate40, polysorbate60, Tween 80, poloxamer, Tai Luoshamu, each ingredient
Mass percentage concentration is 0.1%-10%.
The pH buffer is the combination of disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate or dipotassium hydrogen phosphate, respectively at
Dividing mass percentage concentration is 0.001%-1%.
Removing wrinkle and resisting aging active peptides product form of the present invention includes but is not limited to removing wrinkle and resisting aging Essence, removing wrinkle and resisting aging
Facial mask, removing wrinkle and resisting aging face cream, removing wrinkle and resisting aging emulsion, removing wrinkle and resisting aging gelling agent, medical dressing.
The removing wrinkle and resisting aging active peptides are mainly the skin-protection product or curable product for preparing external preparation for skin.
The present invention is understood in order to be more advantageous to, and the mechanism of action of above-mentioned removing wrinkle and resisting aging active peptides is described as follows:
Tripeptides -1 (Tripeptide-1, No. CAS: 823202-99-9) has the effect of class meat poisoning, by interfering acetyl gallbladder
The release of alkali, block nerves signal transduction, prevents muscle to relax from shrinking, to achieve the purpose that wrinkle reduction.
Argireline (Acetyl Hexapeptide-8, No. CAS: 616204-22-9) is a kind of neurotransmitter suppression
Class polypeptide processed participates in competition synapse-related protein 25 (SyNaptosomal Associated Protein 25, SNAP-25) and exists
The site for melting bubble complex prevents vesica from being released effectively neurotransmitter acetylcholine to influence the formation of complex, thus
Weaken contraction of muscle, prevent the formation of wrinkle, can significantly dispel the dynamics lines such as crow's feet, wrinkles on one's forehead, decree line.
Acetyl group octapeptide -3 (Acetyl Octapeptide-3, No. CAS: 868844-74-0) passes through simulation SNAP-25
Peptide chain N-terminal end sequence and design to obtain, be the extension analog of Argireline, by with melt bubble composite bulk phase off-position
Point combines, to prevent the combination in SNAP-25 and site, and then influences the formation of complex, interferes the release of acetylcholine, hinders
Disconnected Neurotransmission, weakens contraction of muscle, to play crease-resistant effect.
β-alanyl hydroxyprolyl- diaminobutyryl benzyl amide, the novel polypeptide raw material of inventor's independent research, class meat
Toxic action is muscle nicotinic acetylcholine receptor antagonist, by the firm connection with muscle nicotinic acetylcholine receptor, thus
Block nerves transmitter acetylcholine weakens neuromuscular juinction in conjunction with receptor, it is of flaccid muscles and have significant anti-wrinkle effect.
Matrixyl -4 (Palmitoyl Pentapeptide-4), can excite collagen, glycosaminoglycan
(GAGs) synthesis increases skin thickness, to effectively reverse aging, reduces wrinkle.
Palmityl tetrapeptide -7 (Palmitoyl Tetrapeptide-7, No. CAS: 221227-05-0), is immunoglobulin
The segment of IgG can regulate and control the secretion of interleukin-6 (IL-6).IL-6 participates in skin chronic inflammatory reaction, the increasing of IL-6
Skin aging can be accelerated by adding, and palmityl tetrapeptide -7 can reduce the level of IL-6 in ageing processes of skin, to maintain skin again
The balance of cell factor in skin substantially eliminates scytitis, reduces glycosylation damage, reaches delay skin aging with this, increases
The purpose of skin elasticity and compact degree.
Carnosine (L-Carnosine, No. CAS: 305-84-0) is one kind by two kinds of amino acid of Beta-alanine and L-Histidine
The dipeptides of composition has various health-care to human body.Carnosine has powerful oxidation resistance, can remove free radical, chela
Alloy category, anti-ageing reparation.
- 1 copper of tripeptides (copper peptide, Copper Peptide), can promote collagen, elastin, proteoglycans and sugar
Amine glycan (GAGs) largely generates, and increases skin elasticity, firm skin, thus smooth out wrinkles；It is anti-oxidant, free radical is removed, is prolonged
Slow skin aging；Promote epidermal cell proliferation, repairs skin barrier.
Palmityl tripeptides -1 (Palmitoyl Tripeptide-1, Pal-GHK, No. CAS: 147732-56-7), in GHK
Peptide chain N-terminal modify and obtain through palmitinic acid, with better percutaneous abilities, skin can be promoted largely to synthesize collagen, more
Wrinkle is desalinated in glycan, energy firm skin, water lock moisturizing, and deep layer repairs skin.
Palmityl tripeptides -5 (Palmitoyl Tripeptide-5), by activating transforming growth factor-β (TGF-β), thorn
Swashing fibroblast division growth, strength promotes the generation of collagen, supplements extracellular matrix protein, strengthen connective tissue,
The activity that can also inhibit matrix metalloproteinase, prevents collagen from decomposing, to allow skin high resilience, effectively dispels wrinkle
Line.
Palmitoyl oligopeptide (Palmitoyl Oligopeptide) can promote the synthesis of dermal elastin, improve skin
Skin elasticity, promotes compact degree, increases skin softness.
Hexapeptide -9 (Hexapeptide-9), can increase the synthesis of skin corium collagen, increase Laminin ELISA-V, whole
The quantity of mucoprotein promotes the regeneration and reinforcing of dermoepidermal connection (DEJ) plot structure tissue, promotes keratinocyte differentiation, angle
Albumen synthesis recombinates complete table cortex to repair wound, promotes skin regeneration, keeps skin more flexible, reduces wrinkle.
Hexapeptide -11 (Hexapeptide-11) promotes the related gene expression of Skin Cell epimatrix, promotes into fiber finer
Born of the same parents synthesize collagen, elastin laminin, improve skin elasticity and compact degree, improve static wrinkle, to anti-aging.
Acquired beneficial effect includes: the present invention compared with the existing technology
(1) nano-encapsulated is carried out to removing wrinkle and resisting aging active peptides, improves the stability and safety in utilization of polypeptide.
(2) polypeptide increases Transdermal absorption through nano-encapsulated.
(3) removing wrinkle and resisting aging active peptides are higher in the accumulation of skin after nano-encapsulated, and same inventory can achieve
Better removing wrinkle and resisting aging effect.
Detailed description of the invention
The transdermal amount of the cumulative in vitro of Fig. 1 polypeptide and accumulation skin hold-up (for 24 hours)
Specific embodiment
For a better understanding of the present invention, invention is described in detail below with reference to embodiment and attached drawing, but not only
It is limited to embodiment below.
Embodiment 1
Prescription
Preparation method:
1, soybean lecithin, cholesterol, propylene glycol, 1, the 2- hexylene glycol in A phase are taken in prescription ratio, in 40 DEG C of fire-bars
Stirring and dissolving under part, it is spare；
2, tripeptides -1, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate in B phase are taken in prescription ratio, warm water (20 is added
DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 38.6nm.
Embodiment 2
Prescription
Preparation method:
1, soybean lecithin, cholesterol, propylene glycol, 1, the 2- hexylene glycol in A phase are taken in prescription ratio, in 40 DEG C of fire-bars
Stirring and dissolving under part, it is spare；
2, Argireline, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate in B phase are taken in prescription ratio, temperature is added
Water (20 DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 46.4nm.
Embodiment 3
Prescription
Preparation method:
1, soybean lecithin, cholesterol, propylene glycol, 1, the 2- hexylene glycol in A phase are taken in prescription ratio, in 40 DEG C of fire-bars
Stirring and dissolving under part, it is spare；
2, acetyl group octapeptide -3 in B phase, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate are taken in prescription ratio, and temperature is added
Water (20 DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 53.7nm.
Embodiment 4
Prescription
Preparation method:
1, soybean lecithin, cholesterol, propylene glycol, 1, the 2- hexylene glycol in A phase are taken in prescription ratio, in 40 DEG C of fire-bars
Stirring and dissolving under part, it is spare；
2, the β in B phase-alanyl hydroxyprolyl- diaminobutyryl benzyl amide, polysorbas20, phosphoric acid hydrogen is taken in prescription ratio
Disodium, sodium dihydrogen phosphate are added warm water (20 DEG C -35 DEG C), and stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 40.6nm.
Embodiment 5
Prescription
Preparation method:
1, soybean lecithin, cholesterol, propylene glycol, 1, the 2- hexylene glycol in A phase are taken in prescription ratio, in 40 DEG C of fire-bars
Stirring and dissolving under part, it is spare；
2, Matrixyl -4, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate in B phase are taken in prescription ratio, temperature is added
Water (20 DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 48.5nm.
Embodiment 6
Prescription
Preparation method:
1, soybean lecithin, cholesterol, propylene glycol, 1, the 2- hexylene glycol in A phase are taken in prescription ratio, in 40 DEG C of fire-bars
Stirring and dissolving under part, it is spare；
2, palmityl tetrapeptide -7, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate in B phase are taken in prescription ratio, temperature is added
Water (20 DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 47.3nm.
Embodiment 7
Prescription
Preparation method:
1, soybean lecithin, cholesterol, propylene glycol, 1, the 2- hexylene glycol in A phase are taken in prescription ratio, in 40 DEG C of fire-bars
Stirring and dissolving under part, it is spare；
2, carnosine, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate in B phase are taken in prescription ratio, be added warm water (20 DEG C-
35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 46.5nm.
Embodiment 8
Prescription
Preparation method:
1, soybean lecithin, cholesterol, propylene glycol, 1, the 2- hexylene glycol in A phase are taken in prescription ratio, in 40 DEG C of fire-bars
Stirring and dissolving under part, it is spare；
2, -1 copper of tripeptides, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate in B phase are taken in prescription ratio, warm water is added
(20 DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 40.4nm.
Embodiment 9
Prescription
Preparation method:
1, phosphatidyl-ethanolamine, isopropyl myristate, the oleic acid, propylene glycol, 1,3- fourth two in A phase are taken in prescription ratio
Alcohol, the stirring and dissolving under 40 DEG C of heating conditions are spare；
2, palmityl tripeptides -1 in B phase, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate are taken in prescription ratio, and temperature is added
Water (20 DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 26.3nm.
Embodiment 10
Prescription
Preparation method:
1, phosphatidyl-ethanolamine, isopropyl myristate, the oleic acid, propylene glycol, 1,3- fourth two in A phase are taken in prescription ratio
Alcohol, the stirring and dissolving under 40 DEG C of heating conditions are spare；
2, palmityl tripeptides -5 in B phase, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate are taken in prescription ratio, and temperature is added
Water (20 DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 24.6nm.
Embodiment 11
Prescription
Preparation method:
1, phosphatidyl-ethanolamine, isopropyl myristate, the oleic acid, propylene glycol, 1,3- fourth two in A phase are taken in prescription ratio
Alcohol, the stirring and dissolving under 40 DEG C of heating conditions are spare；
2, palmitoyl oligopeptide, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate in B phase are taken in prescription ratio, warm water is added
(20 DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 27.4nm.
Embodiment 12
Prescription
Preparation method:
1, phosphatidyl-ethanolamine, isopropyl myristate, the oleic acid, propylene glycol, 1,3- fourth two in A phase are taken in prescription ratio
Alcohol, the stirring and dissolving under 40 DEG C of heating conditions are spare；
2, hexapeptide -9 in B phase, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate are taken in prescription ratio, and warm water (20 is added
DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 21.8nm.
Embodiment 13
Prescription
Preparation method:
1, phosphatidyl-ethanolamine, isopropyl myristate, the oleic acid, propylene glycol, 1,3- fourth two in A phase are taken in prescription ratio
Alcohol, the stirring and dissolving under 40 DEG C of heating conditions are spare；
2, hexapeptide -11 in B phase, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate are taken in prescription ratio, and warm water (20 is added
DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 23.4nm.
Embodiment 14
Prescription
Preparation method:
1, phosphatidyl-ethanolamine, isopropyl myristate, the oleic acid, propylene glycol, 1,3- fourth two in A phase are taken in prescription ratio
Alcohol, the stirring and dissolving under 40 DEG C of heating conditions are spare；
2, tripeptides -1, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate in B phase are taken in prescription ratio, warm water (20 is added
DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 20.5nm.
Embodiment 15
Prescription
Preparation method:
1, phosphatidyl-ethanolamine, isopropyl myristate, the oleic acid, propylene glycol, 1,3- fourth two in A phase are taken in prescription ratio
Alcohol, the stirring and dissolving under 40 DEG C of heating conditions are spare；
2, Argireline, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate in B phase are taken in prescription ratio, temperature is added
Water (20 DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 27.4nm.
Embodiment 16
Prescription
Preparation method:
1, phosphatidyl-ethanolamine, isopropyl myristate, the oleic acid, propylene glycol, 1,3- fourth two in A phase are taken in prescription ratio
Alcohol, the stirring and dissolving under 40 DEG C of heating conditions are spare；
2, acetyl group octapeptide -3 in B phase, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate are taken in prescription ratio, and temperature is added
Water (20 DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 29.3nm.
Embodiment 17
Prescription
Preparation method:
1, soybean lecithin, cholesterol, propylene glycol, 1, the 2- hexylene glycol in A phase are taken in prescription ratio, in 40 DEG C of fire-bars
Stirring and dissolving under part, it is spare；
2, tripeptides -1, polysorbas20, disodium hydrogen phosphate, sodium dihydrogen phosphate in B phase are taken in prescription ratio, warm water (20 is added
DEG C -35 DEG C), stirring and dissolving is spare；
3, A phase and B are mixed, by high speed shear under the conditions of 20000rpm pre-emulsification；
4, high-pressure homogeneous processing under the conditions of 22500psi by above-mentioned mixed liquor recycles 5 times, obtains the anti-wrinkle of nano-encapsulated
Anti-ageing active peptides.
5, the partial size of removing wrinkle and resisting aging active peptides nano-encapsulated body is detected, obtaining inclusion enclave partial size is 40.6nm.
Comparative example 1
Prescription (1 kilogram of Essence)
Preparation method:
The Sodium Hyaluronate of formula ratio is added to the water, stirring makes to be uniformly mixed, and is then heated to 80~85 DEG C, heat preservation
Stirring makes it be uniformly dispersed.Temperature drop to 40 DEG C hereinafter, be added glycerol, Aloe Vera Gel, tripeptides -1, Cer NP, pungent glycol and 1,
2- hexylene glycol, stirs evenly.With the pH value of 15% triethanolamine tune solution to 5.5 or so.
Comparative example 2
According to the prescription and preparation method of comparative example 1, the Essence of blank is prepared.By embodiment 17 and blank
Essence is compounded according to mass ratio 1:1, is uniformly mixed, is obtained -1 Essence of nano-encapsulated tripeptides containing about 0.1%.
The stability test of 18 removing wrinkle and resisting aging active peptides nano-encapsulated body of embodiment
The removing wrinkle and resisting aging active peptides nano-encapsulated body that embodiment 1-17 is obtained at room temperature, in closed container
It places 30 days, the character and partial size of test sample, test result are shown in Table 1.
1 removing wrinkle and resisting aging active peptides nano-encapsulated body stability test result of table
By result in table 1 it is found that the removing wrinkle and resisting aging active peptides nano-encapsulated body that embodiment 1-17 is obtained is being placed 30 days
Not occurring aggregation, precipitating, lamination afterwards, significant changes also do not occur for partial size, and it is with good stability, it can be realized to work
The nano-encapsulated of property polypeptide.
The removing wrinkle and resisting aging active peptides of 19 nano-encapsulated of embodiment and its compounding stability test
19.1 instruments
Climatic chamber, high performance liquid chromatograph (HPLC)
19.2 test specimens
1 nano-encapsulated tripeptides -1 of embodiment, common -1 Essence of tripeptides of comparative example 1,2 nano-encapsulated of comparative example
- 1 Essence of tripeptides.
19.3 test basis
" Chinese Pharmacopoeia " four 9001 bulk pharmaceutical chemicals of general rule of version in 2015 and preparation stability test direction principle
19.4 experimental conditions and inspection project
Accelerated test: 40 DEG C ± 2 DEG C of climatic chamber, RH75% ± 5% passed through HPLC respectively at the 1st, 2,3,6 month
The content of polypeptide in each sample is detected, to evaluate its stability.
Long term test: 25 DEG C ± 2 DEG C of climatic chamber, RH60% ± 10%, respectively at the 3rd, 6,9,12,18,24,36
The moon detects the content of polypeptide in each sample by HPLC, to evaluate its stability.
19.5 stability test result
1 nano-encapsulated tripeptides -1 of embodiment, common -1 Essence of tripeptides of comparative example 1,2 nano-encapsulated of comparative example
After the sample of -1 Essence of tripeptides is placed 6 months under the conditions of accelerated test, stability data see the table below 2:
Table 2 accelerates 6 months stability test data
1 nano-encapsulated tripeptides -1 of embodiment, common -1 Essence of tripeptides of comparative example 1,2 nano-encapsulated of comparative example
After the sample of -1 Essence of tripeptides is placed 6 months under the conditions of long term test, stability data see the table below 3:
The long-term 6 months stability test data of table 3
By result in table 2 and table 3 it is found that 1 nano-encapsulated tripeptides -1 of embodiment, 2 nano-encapsulated tripeptides -1 of comparative example
For Essence in accelerated test and after long term test 6 months, there are not significant changes in -1 content of tripeptides in product, does not occur
Water-oil separating phenomenon after illustrating that polypeptide compounds after nano-encapsulated and by the polypeptide of nano-encapsulated with matrix, all has good
Stability.In contrast, common -1 Essence of tripeptides of comparative example 1 produces under the conditions of accelerating 6 months and is 6 months long-term
There is different degrees of decline in -1 content of tripeptides in product, and the reduction of content of peptides necessarily leads to the decline of its effect, even
There may be harmful catabolites, have potential hazard to human body.Therefore, it can be improved after nano-encapsulated in active peptides
Stability and safety can obtain superior removing wrinkle and resisting aging effect in the case where identical inventory.
The transdermal amount of 20 cumulative in vitro of embodiment and accumulation skin hold-up test
20.1 instruments
Intellectual drug percutaneous dispersion test instrument, high performance liquid chromatograph (HPLC)
20.2 test specimens
1 nano-encapsulated tripeptides -1 of embodiment, common -1 Essence of tripeptides of comparative example 1,2 nano-encapsulated of comparative example
- 1 Essence of tripeptides
20.3 test methods
Using the percutaneous abilities of rectilinear Franz diffusion cell method evaluation sample.The isolated skin of SD rat abdomen is fixed
Between diffusion cell receiving chamber and supply chamber, take 1g sample in the skin surface of supply chamber, effective diffusion area 3.14cm2, connect
Physiological saline is added in receives pond as receiving liquid, emptying bubble completely attaches to corium side and receiving liquid, 32 DEG C, 300r/min
Stirring diffusion.Respectively at 4h, 8h, 12h, 16h, 20h, receiving liquid 0.5mL is taken for 24 hours, and the reception of equivalent constant temperature blank is replenished in time
Liquid.Concentration through polypeptide in HPLC measurement receiving liquid, the polypeptide units area accumulation for calculating different time as follows are transdermal
Amount:
Wherein: QnTo accumulate transdermal amount；CnPeptide concentration in receiving liquid when for the sub-sampling；V is physiological saline in reception tank
Volume；CiPeptide concentration in receiving liquid when for the 1st time to previous sample；ViFor each sample volume；A is effective diffusion area.
After for 24 hours, skin is removed, ultrapure water shreds after washing away sample raffinate, addition ultrapure water homogenized, ultrasonic 5min,
10000r/min is centrifuged 10min, and supernatant is taken to detect through HPLC method, calculates polypeptide units areas of skin as follows and is detained
Amount:
Qs=Cs×V/A
Wherein, QsTo accumulate hold-up；CsPeptide masses concentration in the skin samples liquid measured for sampling time point；V is upper
Supernatant volume；A is effective diffusion area.
20.4 test results
1 nano-encapsulated tripeptides -1 of embodiment, common -1 Essence of tripeptides of comparative example 1,2 nano-encapsulated of comparative example
- 1 Essence of tripeptides is after percutaneous dispersion test for 24 hours, the transdermal amount of the cumulative in vitro of polypeptide and accumulation skin hold-up in sample
As shown in Figure 1.
Fig. 1 the results show that 1 nano-encapsulated tripeptides -1 of embodiment through the transdermal amount of accumulation for 24 hours be 65.31 μ g/cm2, accumulation
Skin hold-up is 32.52 μ g/cm2, the transdermal amount of accumulation of common -1 Essence of tripeptides of comparative example 1 for 24 hours is 29.10 μ g/
cm2, accumulation skin hold-up is 4.62 μ g/cm2, the transdermal amount of accumulation of -1 Essence of 2 nano-encapsulated tripeptides of comparative example is
65.42μg/cm2, accumulation skin hold-up is 32.97 μ g/cm2.It follows that polypeptide is before nano-encapsulated, due to skin screen
The limitation of barrier, transdermal amount and skin hold-up are lower, and after nano-encapsulated, the transdermal amount and skin hold-up of polypeptide
It is significantly increased, especially skin hold-up improves more obvious, show that Transdermal absorption can be enhanced in polypeptide after nano-encapsulated,
And it accumulates in skin, more efficiently plays its removing wrinkle and resisting aging effect in skin.The polypeptide and matrix of nano-encapsulated
The Transdermal absorption of polypeptide and skin in product are had no effect on after compounding to be detained, and still there is biggish accumulation skin hold-up, favorably
In its skin removing wrinkle and resisting aging effect of enhancing.
The test of 21 anti-aging of embodiment
21.1 subjects
120 30-50 years old healthy womens, are randomly divided into 4 groups, average every group of 30 people.
21.2 test specimens
1 nano-encapsulated tripeptides -1 of embodiment, common -1 Essence of tripeptides of comparative example 1,2 nano-encapsulated of comparative example
- 1 Essence of tripeptides, using placebo as blank control.
21.3 test equipments
The skin elasticity Cotometer MPA580 master of German Courage+Khazaka company (German CK company) manufacture
Machine, used probe are Reviscometer RV600 elastic fibrous tissue test probes.
21.4 test operations
Blank R2, R5, R7 value of 30min after first measurement face area cleans,
Wherein R2=Ua/Uf, R5=Ur/Ue, R7=Ur/Uf,
Ua: the recovery value of skin when from cancellation negative pressure to follow-on test skin surface repressurization next time；
Uf: skin maximum amount of tension when having negative pressure；
Ur: after cancelling negative pressure 0.1s, the recovery value and visco-elastic portions value or plastic value of skin；
Ue: after constant negative pressure is added on skin, the amount of tension of skin, positioning elastic part amount of tension when 0.1s；
Then sample is spread evenly across face, twice a day, adhere to sooner or later using, must not use other cosmetics, even
Continuous to use 4 weeks, after distinguishing test record test area before administration skin R2, R5, R7 value.The test of the same subject by
The same survey crew completes.
21.5 test results
Improve the function of skin elasticity anti-aging by comparing skin R2, R5, R7 value variation of administration front and back to assess product
Effect, the variation of R2, R5, R7 value are as shown in table 4 below:
The situation of change of 4 each group of table administration front and back skin R2, R5, R7 value
Note: for R2, R5, R7 value closer to 1, skin elasticity is better.
From the data in the table, relative to placebo, after being used 4 weeks in the identical situation of activity component concentration, respectively
R2, R5, R7 value that test group measures significantly improve, wherein being received using 1 nano-encapsulated tripeptides -1 of embodiment and comparative example 2
After 4 weeks, skin R2, R5, R7 value measured measures rice package -1 Essence of tripeptides than common -1 Essence of tripeptides of comparative example 1
Value it is higher, before testing after R2, R5, R7 value change rate it is bigger, show that polypeptide can significantly improve skin after nano-encapsulated
Skin elasticity anti-aging function.
The above content is the further details of explanations for combining specific preferred embodiment to be the present invention, but not
Indicate that specific implementation of the invention is limited to these explanations.For those skilled in the art,
Under the premise of not departing from present inventive concept, several simple deductions or replacement can also be made, is regarded as belonging to of the invention
Protection scope.
Claims (10)
1. a kind of removing wrinkle and resisting aging active peptides, which is characterized in that the removing wrinkle and resisting aging active peptides are to be wrapped in nano-encapsulated body
In.
2. by removing wrinkle and resisting aging active peptides described in claim 1, which is characterized in that the removing wrinkle and resisting aging active peptides are tripeptides-
1, Argireline, acetyl group octapeptide -3, β-alanyl hydroxyprolyl- diaminobutyryl benzyl amide, Matrixyl -4,
Palmityl tetrapeptide -7, carnosine, -1 copper of tripeptides, palmityl tripeptides -1, palmityl tripeptides -5, palmitoyl oligopeptide, hexapeptide -9, hexapeptide -
11, each composition quality percentage concentration is 0.0001%-5%.
3. by removing wrinkle and resisting aging active peptides described in claim 1, which is characterized in that the package is wrapped with lipid components
It wraps up in.
4. by removing wrinkle and resisting aging active peptides described in claim 3, which is characterized in that the lipid components are soybean lecithin, egg
Yellow lecithin, phosphatidyl-ethanolamine, lysophosphatidyl choline, cholesterol, lauric acid, myristic acid, palmitinic acid, stearic acid, meat
The combination of one or more of isopropyl myristate, isopropyl palmitate, oleic acid, glyceryl linoleate, vitamin E, respectively at
Dividing mass percentage concentration is 2%-20%.
5. by removing wrinkle and resisting aging active peptides described in claim 1, which is characterized in that the nano-encapsulated body further include it is following at
Point: polyalcohol, surfactant, pH buffer.
6. by removing wrinkle and resisting aging active peptides described in claim 5, which is characterized in that the polyalcohol is propylene glycol, glycerol, 1,2-
Hexylene glycol, the combination of one or more of 1,3-BDO, each composition quality percentage concentration are 2%-20%.
7. by removing wrinkle and resisting aging active peptides described in claim 5, which is characterized in that the surfactant is polysorbas20, tween
40, polysorbate60, Tween 80, poloxamer, Tai Luoshamu, each composition quality percentage concentration are 0.1%-10%.
8. by removing wrinkle and resisting aging active peptides described in claim 5, which is characterized in that the pH buffer is disodium hydrogen phosphate, phosphorus
The combination of acid dihydride sodium, potassium dihydrogen phosphate or dipotassium hydrogen phosphate, each composition quality percentage concentration are 0.001%-1%.
9. by removing wrinkle and resisting aging active peptides described in claim 1-8 any claim, which is characterized in that the removing wrinkle and resisting aging is living
Property polypeptide products form include but is not limited to removing wrinkle and resisting aging Essence, removing wrinkle and resisting aging facial mask, removing wrinkle and resisting aging face cream, removing wrinkle and resisting aging cream
Agent, removing wrinkle and resisting aging gelling agent, medical dressing.
10. by removing wrinkle and resisting aging active peptides described in claim 1-8 any claim, which is characterized in that the removing wrinkle and resisting aging
Active peptides are mainly the skin-protection product or curable product for preparing external preparation for skin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910057506.9A CN109528545A (en) | 2019-01-22 | 2019-01-22 | A kind of removing wrinkle and resisting aging active peptides |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910057506.9A CN109528545A (en) | 2019-01-22 | 2019-01-22 | A kind of removing wrinkle and resisting aging active peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109528545A true CN109528545A (en) | 2019-03-29 |
Family
ID=65838089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910057506.9A Pending CN109528545A (en) | 2019-01-22 | 2019-01-22 | A kind of removing wrinkle and resisting aging active peptides |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109528545A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109966169A (en) * | 2019-04-23 | 2019-07-05 | 嫦娥创新（武汉）生物科技有限公司 | A kind of external preparation for skin peptide composition and its application |
| CN110721148A (en) * | 2019-11-11 | 2020-01-24 | 奢脉国际化妆品(北京)有限公司 | Multidirectional pulling and tightening polypeptide essence and preparation method thereof |
| CN110840752A (en) * | 2019-12-19 | 2020-02-28 | 宇肽生物(东莞)有限公司 | Water-in-oil wrinkle-removing polypeptide composition |
| CN111631985A (en) * | 2020-06-18 | 2020-09-08 | 北京斯利安药业有限公司 | Anti-wrinkle composition containing folic acid, eye cream and preparation method thereof |
| CN112386506A (en) * | 2019-08-16 | 2021-02-23 | 上海可米日化股份有限公司 | Skin care gel containing peptide-alcohol liposome compound and preparation method thereof |
| CN112716825A (en) * | 2021-01-15 | 2021-04-30 | 四川天晟制药有限公司 | Anti-aging polypeptide and natural plant composition |
| CN112716826A (en) * | 2021-02-26 | 2021-04-30 | 山东科思达美生物科技有限公司 | Polypeptide composition with long-acting wrinkle removing and skin elasticity improving functions |
| CN112741782A (en) * | 2019-10-31 | 2021-05-04 | 湖北健翔生物制药有限公司 | Cosmetic tablet containing GHK-Cu liposome |
| CN112807240A (en) * | 2021-02-26 | 2021-05-18 | 山东科思达美生物科技有限公司 | Polypeptide composition for removing wrinkles and resisting senility |
| CN114010526A (en) * | 2021-12-01 | 2022-02-08 | 宇肽生物(东莞)有限公司 | Anti-aging polypeptide composition and application thereof |
| CN114933631A (en) * | 2022-06-01 | 2022-08-23 | 深圳市维琪医药研发有限公司 | Peptide derivative isomer, and cosmetic composition or pharmaceutical composition and use thereof |
| CN117338624A (en) * | 2023-09-25 | 2024-01-05 | 揭阳市嘉胜日用精细化工有限公司 | Mild and absorbable whitening and anti-wrinkle composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106726668A (en) * | 2016-11-19 | 2017-05-31 | 诺斯贝尔化妆品股份有限公司 | A kind of many peptidoliposome raw materials used in cosmetics |
| CN106963688A (en) * | 2017-04-24 | 2017-07-21 | 华南协同创新研究院 | It is a kind of containing plant extracts complex polypeptide liposome composition and preparation method thereof and in the application of anti-wrinkle product |
| CN109044921A (en) * | 2018-10-30 | 2018-12-21 | 武汉百思凯瑞生物科技有限公司 | One kind is anti-ageing to convey nano-lipid vesica and its preparation method and application altogether |
-
2019
- 2019-01-22 CN CN201910057506.9A patent/CN109528545A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106726668A (en) * | 2016-11-19 | 2017-05-31 | 诺斯贝尔化妆品股份有限公司 | A kind of many peptidoliposome raw materials used in cosmetics |
| CN106963688A (en) * | 2017-04-24 | 2017-07-21 | 华南协同创新研究院 | It is a kind of containing plant extracts complex polypeptide liposome composition and preparation method thereof and in the application of anti-wrinkle product |
| CN109044921A (en) * | 2018-10-30 | 2018-12-21 | 武汉百思凯瑞生物科技有限公司 | One kind is anti-ageing to convey nano-lipid vesica and its preparation method and application altogether |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109966169A (en) * | 2019-04-23 | 2019-07-05 | 嫦娥创新（武汉）生物科技有限公司 | A kind of external preparation for skin peptide composition and its application |
| CN112386506A (en) * | 2019-08-16 | 2021-02-23 | 上海可米日化股份有限公司 | Skin care gel containing peptide-alcohol liposome compound and preparation method thereof |
| CN112741782A (en) * | 2019-10-31 | 2021-05-04 | 湖北健翔生物制药有限公司 | Cosmetic tablet containing GHK-Cu liposome |
| CN110721148A (en) * | 2019-11-11 | 2020-01-24 | 奢脉国际化妆品(北京)有限公司 | Multidirectional pulling and tightening polypeptide essence and preparation method thereof |
| CN110840752A (en) * | 2019-12-19 | 2020-02-28 | 宇肽生物(东莞)有限公司 | Water-in-oil wrinkle-removing polypeptide composition |
| CN111631985B (en) * | 2020-06-18 | 2022-08-05 | 北京斯利安药业有限公司 | Anti-wrinkle composition containing folic acid, eye cream and preparation method thereof |
| CN111631985A (en) * | 2020-06-18 | 2020-09-08 | 北京斯利安药业有限公司 | Anti-wrinkle composition containing folic acid, eye cream and preparation method thereof |
| CN112716825A (en) * | 2021-01-15 | 2021-04-30 | 四川天晟制药有限公司 | Anti-aging polypeptide and natural plant composition |
| CN112716826A (en) * | 2021-02-26 | 2021-04-30 | 山东科思达美生物科技有限公司 | Polypeptide composition with long-acting wrinkle removing and skin elasticity improving functions |
| CN112807240A (en) * | 2021-02-26 | 2021-05-18 | 山东科思达美生物科技有限公司 | Polypeptide composition for removing wrinkles and resisting senility |
| CN114010526A (en) * | 2021-12-01 | 2022-02-08 | 宇肽生物(东莞)有限公司 | Anti-aging polypeptide composition and application thereof |
| CN114933631A (en) * | 2022-06-01 | 2022-08-23 | 深圳市维琪医药研发有限公司 | Peptide derivative isomer, and cosmetic composition or pharmaceutical composition and use thereof |
| CN117338624A (en) * | 2023-09-25 | 2024-01-05 | 揭阳市嘉胜日用精细化工有限公司 | Mild and absorbable whitening and anti-wrinkle composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109528545A (en) | A kind of removing wrinkle and resisting aging active peptides | |
| CN106038351B (en) | It is a kind of for desalinating the peptide composition of wrinkle | |
| US11331305B2 (en) | Peptides for skin rejuvenation and methods of using the same | |
| CN109432395A (en) | A kind of whitening spot-removing active peptides | |
| AU2017368136B2 (en) | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | |
| US9115176B2 (en) | Compounds, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same | |
| KR20140043727A (en) | Peptides useful in the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions | |
| EP2957283B1 (en) | Process for identification of medicaments for acceleration of wound healing | |
| CN109568169A (en) | A kind of active peptides of tool hair growth effect | |
| WO2007087738A1 (en) | Biologically active tripeptides and copper complexes and salts thereof | |
| CN110840752A (en) | Water-in-oil wrinkle-removing polypeptide composition | |
| WO2000076528A2 (en) | Pharmaceutical preparation containing proteins | |
| CN110151597A (en) | A kind of polypeptide repair latex and preparation method thereof | |
| CN109498798A (en) | One kind is releived antiallergic active peptides | |
| CN109432396A (en) | A kind of antibacterial anti-acne active peptides | |
| CN116509748A (en) | Anti-wrinkle composition and preparation method and application thereof | |
| CN102037133B (en) | The β thymosin fragments improved | |
| CN109453365A (en) | A kind of eye haustra -dsipelling active peptides | |
| US20230256050A1 (en) | Compositions, methods and uses comprising teneurin c-terminal associated peptide -1 (tcap-1) for enhancing muscle performance | |
| KR100667462B1 (en) | Skin cosmetic compositions | |
| CN115337223A (en) | Anti-wrinkle composition and application thereof | |
| WO2023200875A1 (en) | Octapeptide for topical application | |
| CN110876698A (en) | Active composition for regulating microenvironment of skin cells as well as preparation method and application thereof | |
| CN113509441A (en) | Polypeptide liposome containing fatty acid and preparation method thereof | |
| CN118108793A (en) | Percutaneous absorption type anti-aging active peptide derivative and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190329 |